Company Analysis
Sign in

Lifecore Biomedical, Inc. (LFCR)

Nasdaq: LFCR · Pharmaceutical Preparations · Chaska, MN · filing with the SEC since 1996
Full chart Alerts Compare
Grade4.1
◀ Past 4.2● Present 4.2▶ Future 3.9
3 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

The grade of Lifecore Biomedical, Inc.

Nine metrics read from its own filings, by tense
Headline grade
4.1/10
◀ Past4.225% of the headline
● Present4.235% of the headline
▶ Future3.940% of the headline

All three tenses have at least two readings, so the archetype blend applies as printed.

Of the nine metrics, 6 read as filed from the record and 3 are SI estimates, each with its reasoning, its confidence and what would change it on its card.

◀ Past

What did they actually do?

4.2/1025% of the headline grade · 2 of 3 filed, 1 estimated

Surviving crises

as filed
0.4/10

Has it survived what it has been through?

25 warning events since 2017; the latest 2025-08-18.

weight 22% of this tense · 4th percentile among 497 sector filers · read for itself

From the record

Lifecore Biomedical, Inc.'s filings since 2017 show 25 warning events of 4 kinds: a notice about its exchange listing (8-K item 3.01, 10 times, the latest 2024-06-07); a warning not to rely on past financial statements (8-K item 4.02, 3 times, the latest 2023-10-31); an auditor change (8-K item 4.01, 3 times, the latest 2025-08-18); a late-report notice (Form NT 10-K or NT 10-Q, 9 times, the latest 2024-08-12) (its current reports).

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Track record

as filed
4.8/10

What has it actually done, year after year?

-14.9% a year over 9 filed years; profitable in 4 of 9.

weight 45% of this tense · 48th percentile among 323 sector filers · read for its customers

From the record

Lifecore Biomedical, Inc.'s 9 filed years say what it did: revenue went from $470 million in fiscal 2017 to $129 million in fiscal 2025, down 14.9% a year; it rose in 5 of 8 years; the deepest fall was 82% from fiscal 2019 to fiscal 2021; net income was positive in 4 of 9 of those years (its annual reports).

What it rests on

  • revenue growth over the filed span-14.9%bottom 17% of its family
  • the share of years revenue rosetop 48% of its family
  • the share of filed years with a profittop 17% of its family
  • the deepest fall from a revenue peak81.9%bottom 39% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Shareholder treatment

SI estimate
5.8/10

How has it treated the people who own it?

SI estimate 5.8/10, confidence 20 of 100 (family median).

weight 33% of this tense · 50th percentile among 295 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate
Fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income, so the desk assumes the typical reading of its industry family, the median of 295 members with one.
What the record cannot read
Fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
How it was reasoned
family median, 295 readings behind it.
Confidence
20 of 100
What would change it
Its next annual report on file with the inputs replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Lifecore Biomedical, Inc.'s shareholder treatment is put at 5.8 of 10 with a confidence of 20 of 100, because fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income, so the desk assumes the typical reading of its industry family, the median of 295 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.

● Present

What are they doing right now?

4.2/1035% of the headline grade · 2 of 3 filed, 1 estimated

Financial health

SI estimate
5.1/10

Is it financially healthy right now?

SI estimate 5.1/10, confidence 20 of 100 (family median).

weight 45% of this tense · 50th percentile among 480 sector filers · read for itself

SI estimate Inferred, not read as filed

Why it is an estimate
Fewer than two of the four checks can be read, so the desk assumes the typical reading of its industry family, the median of 480 members with one.
What the record cannot read
Fewer than two of the four checks can be read.
How it was reasoned
family median, 480 readings behind it.
Confidence
20 of 100
What would change it
Its next annual report on file with the inputs replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Lifecore Biomedical, Inc.'s financial health is put at 5.1 of 10 with a confidence of 20 of 100, because fewer than two of the four checks can be read, so the desk assumes the typical reading of its industry family, the median of 480 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.

Industry position

as filed
5.9/10

How strong is its position in its industry?

top 41% of 315 in its family; net margin -30%.

weight 22% of this tense · 59th percentile among 315 sector filers · read for its customers

From the record

Lifecore Biomedical, Inc.'s standing among 315 graded names in its industry family: revenue of $129 million in fiscal 2025 ranks in the top 33% by size; a net margin of -30% ranks in the top 35%; revenue growth of 5% a year over the last 3 filed years ranks in the bottom 46% (its annual reports).

What it rests on

  • revenue against the family$129Mtop 33% of its family
  • net margin-30.0%top 35% of its family
  • three-year revenue growth5.0%bottom 46% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Leadership

as filed
1.8/10

What are the people in charge doing?

bottom 18% of 315 in its family for leadership; chief executive since 2024.

weight 33% of this tense · 18th percentile among 315 sector filers · read for its shareholders

From the record

Lifecore Biomedical, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Josephs, Paul (Chief Executive Officer, as filed), filing under that title since 2024-05-22, 2.5 years (bottom 28% of its family); most of the 12 officers and directors filing now have filed since the record of its people begins (2024-08-19), a floor of 2.4 years the record cannot see past, so that part is not read; 13 officer or director changes were reported on Form 8-K since 2023-11-13, against the 12 people in charge now (bottom 9%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

What it rests on

  • officer and director changes on Form 8-K, against the people in charge13 in three years among 12 peoplebottom 9% of its family
  • the chief executive's years on the record2.5 yearsbottom 28% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

▶ Future

What are they set up to do next?

3.9/1040% of the headline grade · 2 of 3 filed, 1 estimated

Room to expand

SI estimate
0.1/10

How much room does it have to grow?

SI estimate 0.1/10, confidence 35 of 100 (one part).

weight 33% of this tense · 1st percentile among 479 sector filers · read for itself

SI estimate Inferred, not read as filed

Why it is an estimate
Read from one part only, cash less debt against assets, which ranks in the bottom 1% of 479 in its family; the record does not carry two of the four parts: cash less debt against assets, cash from operations less capital spending against revenue, gross margin, research against revenue.
What the record cannot read
The record does not carry two of the four parts: cash less debt against assets, cash from operations less capital spending against revenue, gross margin, research against revenue.
How it was reasoned
one part: cash less debt against assets, the one part on file, ranked among 479 in its family.
Confidence
35 of 100
What would change it
A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Lifecore Biomedical, Inc.'s room to expand is put at 0.1 of 10 with a confidence of 35 of 100, because read from one part only, cash less debt against assets, which ranks in the bottom 1% of 479 in its family; the record does not carry two of the four parts: cash less debt against assets, cash from operations less capital spending against revenue, gross margin, research against revenue. A filing that carries the missing parts replaces this estimate with the filed reading.

Growth drivers

as filed
5.8/10

What could actually drive growth from here?

top 42% of 306 in its family for growth drivers.

weight 45% of this tense · 58th percentile among 306 sector filers · read for its customers

From the record

Lifecore Biomedical, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 5% a year over the last three filed years against -14.9% over all 9, speeding up (top 14% of its family); the newest year grew 0.5% (bottom 40%); research spending grew 1.8% a year (top 50%); capital spending grew -8.7% a year (top 46%) (its annual reports). Lifecore Biomedical, Inc. reported 2 product lines in fiscal 2025: Contract Development and Manufacturing Organization at $90 million (70%), HA Manufacturing at $39 million (30%); 1 of 2 grew against the year before (its annual report).

What it rests on

  • three-year growth against the whole span+20.0 points a yeartop 14% of its family
  • the newest year's revenue growth0.5%bottom 40% of its family
  • three-year growth of research spending1.8%top 50% of its family
  • three-year growth of capital spending-8.7%top 46% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Expectations vs reality

as filed
5.6/10

Did its newest year beat what its own record pointed to?

top 44% of 233 in its family for expectations against reality.

weight 22% of this tense · 56th percentile among 233 sector filers · read for its shareholders

From the record

Lifecore Biomedical, Inc.'s newest year against its own record: revenue of $129 million in fiscal 2025 came in 6.4% below the $138 million its prior three years' pace pointed to (bottom 43% of its family); net income of $39 million against a prior three-year average of $68 million (top 36%); a net margin of -30% against -64% before (top 40%) (its annual reports).

What it rests on

  • revenue against the prior three years' pace-6.4%bottom 43% of its family
  • net income against the prior three years' average+43%top 36% of its family
  • net margin against its prior average+33.9 pointstop 40% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made

SI Assistanton LFCR · research, not advice